ACADIA Pharmaceuticals Inc. (ACAD) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID rating (50/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+103.4% (NI vs OCF)).
As of 2026-11-02, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.59 (-0.82% 1D, market cap $3.58B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 14/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable D (50/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 6.26 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While ACAD currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Company leadership has skin in the game with net positive insider conviction.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.57) and Max Pain ($21.62) forces dealer call-delta covering toward $32.51.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ACADIA Pharmaceuticals Inc. (ACAD) slipped -0.82% to $20.59, trading at 18% of its 52-week range ($18.39 – $30.96). Weak 50/100 RQD score compounded by SEC accrual divergence (+103.4% (NI vs OCF)).
Yahoo Finance Singapore report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, October 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACAD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACAD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ACADIA Pharmaceuticals Inc. (ACAD) ranks #290 by composite RQD confidence (50/100, grade D) and #193 by equity capitalization ($3.58B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with ACAD at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACAD
ACTIVE
ACADIA Pharmaceuticals Inc. | D | 50/100 | 9.1x | 91.7% | 7.9% | -0.82% | $3.58B | Benchmark Subject |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.60B | /amlx-vs-acad → |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-acad → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.64B | /xene-vs-acad → |
| PBLS Parabilis Medicines Inc. | D | 47/100 | — | — | — | -1.32% | $3.50B | /pbls-vs-acad → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ACADIA Pharmaceuticals Inc. (ACAD) reported GAAP revenue of $1.07B (+11.9% vs. FY2024 revenue of $957.8M , and +47.5% cumulative change since FY2023) , GAAP net income of $391.0M, operating cash flow of $109.8M, and free cash flow of $105.1M (-33.1% YoY). On the balance sheet, ACAD closed FY2025 with $1.56B in total assets against $0 in total debt (Altman Z-Score: 6.26, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.07B | $391.0M | $109.8M | $105.1M | $1.56B | — |
| FY2024 (FY) | 2024-12-31 | $957.8M | $226.0M | $157.7M | $157.2M | $1.19B | — |
| FY2023 (FY) | 2023-12-31 | $726.4M | -$61.0M | $16.7M | $16.7M | — | — |
As of 2026-11-02, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.59 (-0.82% 1D, market cap $3.58B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 14/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable D (50/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.
ACAD last traded at $20.59 (-0.82% on volume of 1,137,550 shares), positioning the stock -12.64% below its 50-day simple moving average ($23.57) and -12.94% below its 200-day simple moving average ($23.65). Across its 52-week range of $18.39 to $30.96, ACAD sits at the 17.5% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($19.31 to $21.87).
Why ACAD Stock slipped -0.82% Today — RQD Quant Desk Flash. Weak 50/100 RQD score compounded by SEC accrual divergence (+103.4% (NI vs OCF)).
Per the Roarable RQD rating, ACAD scores 50 out of 100, a grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 8/20 (ROIC 7.9%; FCF yield 2.94%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 15/20 (Altman Z 6.26; Piotroski F 7/9; Debt/Equity 0.5). The two weakest pillars, cash engine and macro fit, are the ones most relevant to a prospective investor: the rating indicates that cash-generation quality and sector-sensitivity are where the case is least supported today. The strongest pillar, balance sheet, indicates the company is not presenting obvious solvency stress by the metrics cited. Upside drivers implied by the data are the insider-conviction and balance-sheet strength; valuation tradeoffs are visible in a trailing P/E of 9.1 against an EV/EBITDA of 31.2, which signals that the earnings multiple and the enterprise-value multiple tell different stories and warrant reconciliation before any conclusion is drawn.
ACADIA Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it operates with a market capitalization of $3.6B. Source data does not describe the company's specific products, customers, or revenue model beyond the sector and industry classification. Gross margin is reported at 91.7%, indicating a high gross-margin profile per the market data.
Per the news feed, recent items include a market-wire report on ACAD stock price and history, an RBC Capital reiteration of the stock rating tied to patent developments, a Stock Titan notice of a UBS conference chat on Nov. 17, and a Yahoo Finance headline referencing patent and Phase 2 progress. One item is flagged RED on the RISK WATCH label, a Simply Wall St piece noting a stock drop and asking what is driving attention. Per the Butterfly Supply-Chain Graph, the sole proprietary signal is an ACCOUNTING_MIRAGE signal, terminal label "ACCRUAL & WORKING CAPITAL WATCH," with severity score 82 and a BEARISH direction. The signal states that net income growth (+73%) outpaced operating cash flow growth (-30.4%), with a +103.4% cash conversion gap and working-capital and receivables expansion of +31.1%, and recommends monitoring the upcoming 10-Q for cash realization.
Real-time company headlines, analyst actions, and sector developments for ACADIA Pharmaceuticals Inc. (ACAD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Welcome to the ACAD (ACADIA Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ACAD, but look at what you are paying: 9.1x trailing P/E with 91.7% gross margins. Unless ACADIA Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ACAD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $20.76 (52-wk range $18.39 - $30.96), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).